Regal Investment Advisors LLC raised its position in shares of Sanofi SA (NYSE:SNY) by 16.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 9,325 shares of the company’s stock after purchasing an additional 1,323 shares during the quarter. Regal Investment Advisors LLC’s holdings in Sanofi were worth $413,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its position in Sanofi by 15,317.9% during the third quarter. Bank of New York Mellon Corp now owns 156,183 shares of the company’s stock valued at $6,976,000 after buying an additional 155,170 shares during the period. JPMorgan Chase & Co. lifted its position in Sanofi by 342.1% during the third quarter. JPMorgan Chase & Co. now owns 147,330 shares of the company’s stock valued at $6,581,000 after buying an additional 114,008 shares during the period. Teachers Advisors LLC purchased a new position in Sanofi during the third quarter valued at $31,557,000. Virtu Financial LLC purchased a new position in Sanofi during the fourth quarter valued at $460,000. Finally, Bank of Montreal Can lifted its position in Sanofi by 953.7% during the fourth quarter. Bank of Montreal Can now owns 439,423 shares of the company’s stock valued at $19,075,000 after buying an additional 397,720 shares during the period. Institutional investors and hedge funds own 7.04% of the company’s stock.

In other news, major shareholder Sanofi sold 131,115 shares of Sanofi stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $412.17, for a total value of $54,041,669.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.00% of the stock is owned by insiders.

SNY has been the subject of several recent research reports. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $48.00 price objective for the company in a research report on Monday, February 4th. HC Wainwright reissued a “buy” rating on shares of Sanofi in a research report on Thursday, February 28th. Finally, TheStreet lowered Sanofi from a “b” rating to a “c+” rating in a research report on Thursday, February 7th. Eight analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $51.00.

Shares of SNY traded up $0.17 during trading hours on Friday, hitting $42.28. The company had a trading volume of 1,194,253 shares, compared to its average volume of 1,026,968. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. The firm has a market cap of $106.04 billion, a PE ratio of 13.51, a P/E/G ratio of 2.41 and a beta of 0.67. Sanofi SA has a 52-week low of $37.67 and a 52-week high of $45.62.

Sanofi (NYSE:SNY) last posted its quarterly earnings results on Friday, April 26th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.07. The firm had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.34 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. Sanofi’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.28 EPS. As a group, sell-side analysts anticipate that Sanofi SA will post 3.1 EPS for the current year.

The business also recently declared an annual dividend, which will be paid on Friday, May 31st. Stockholders of record on Wednesday, May 8th will be given a $1.7395 dividend. This represents a dividend yield of 4.2%. The ex-dividend date is Tuesday, May 7th. Sanofi’s dividend payout ratio is presently 37.38%.

TRADEMARK VIOLATION NOTICE: “Regal Investment Advisors LLC Purchases 1,323 Shares of Sanofi SA (SNY)” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at

Sanofi Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

See Also: Why is the Consumer Price Index (CPI) important?

Want to see what other hedge funds are holding SNY? Visit to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.